Tony Kushner Baffled By Susan Sarandon’s Opposition To Hillary Clinton / Queerty. Oh Susan, what are you doing? For months the Bernie Sanders campaign has been using the actress as a surrogate (basically someone hired to repeat talking points) and she. When asked if she would vote for. MSNBC didn’t identify him as such but he sure was behaving like one.)Kushner likes Hillary. If he fails to get the nomination, yeah, you’ll be disappointed, but you can still participated in the process for getting Hillary into office.“I think she’s absolutely the best shot to win. The I couldn’t possibly vote for Hillary Clinton thing from someone like! I don’t know what’s going to be nominated or who’s going to be nominated on the other side of things, but it’s terrifying.”. Coles is a founding investor and the chairman and chief executive officer of Yumanity Therapeutics. In addition to his role at Yumanity, Dr. Location and software training workshops. Our goal is to get you to the right place at the right time and help you capture the images you imagine. Tony Bennett, who turns 90 on August 3, and his wife, Susan Benedetto, have been married since 2007. However, the legendary singer and Benedetto have been together. Coles serves as chairman and chief executive officer of TRATE Enterprises, LLC. Coles was chairman and chief executive officer of Onyx Pharmaceuticals, Inc., which was acquired by Amgen in late 2. Under his leadership, Onyx introduced two new innovative cancer medicines to patients and established the company’s international presence outside of the U. S. Prior to joining Onyx in 2. NPS Pharmaceuticals, Inc. Before joining NPS Pharmaceuticals in 2. Dr. Coles was senior vice president of commercial operations at Vertex Pharmaceuticals Inc., and earlier, held a number of executive positions at Bristol- Myers Squibb Company. Additionally, from 1. Dr. Coles held a number of positions of increasing responsibility at Merck & Co., Inc. Dr. Coles completed his cardiology and internal medicine training at Massachusetts General Hospital and was a research fellow at Harvard Medical School. Tony And Susan PdfColes currently serves as a member of the board of directors of Mc. Kesson Corporation (NYSE: MCK), is vice chair of the board of trustees for Johns Hopkins University and is a member of the board of trustees for Johns Hopkins Medicine. Coles was named to the NIH working group tasked with charting the course for President Obama’s Precision Medicine Initiative, now part of the PMI Cohort Program Advisory Panel. Coles also serves as a member of the council for the Smithsonian. Mohsen is chief business officer of Yumanity Therapeutics. Prior to Yumanity, Mr. Mohsen served as country manager in Canada at Cubist Pharmaceuticals (acquired by Merck), where he led the company. Founded in 1967, Lisson Gallery is one of the most influential contemporary art galleries in the world, showing 45 innovative and international artists. This web page was first published on July 25, 1997, and is maintained by Susan Mueller. Sauter, Professor of Information Systems, College of. Coldwell Banker Mid-Plaza Real Estate is the oldest, largest, and most trusted Coldwell Banker office in Brooklyn. For over 20 years we have specialized in all. Super Shoes Home Page. Sign-up to receive special offers, the latest news and discounts! In this role, he led the launch of DIFICID (fidaxomicin) in Canada and oversaw the company. Mohsen was vice president, strategy and business operations for Optimer Pharmaceuticals (acquired by Cubist), and helped establish the commercial infrastructure and led U. S. Mohsen held strategic and operational roles of increasing responsibility at Pfizer from 1. Mr. Rhodes is chief scientific officer of Yumanity Therapeutics. Prior to Yumanity, Dr. Rhodes served as vice president, neurology discovery at Biogen Idec, where he led a scientific organization focused on discovery and early development of novel protein and small molecule drugs for the treatment of neurodegenerative diseases. During his tenure at Biogen Idec, Dr. Rhodes and his team played a major role in the preclinical development of BIIB0. Phase 1 proof- of- concept study in Alzheimer. BIIB0. 37 will enter Phase 3 trials later this year. In addition to drug discovery activities, Dr. Rhodes and his team led preclinical research studies in the area of translational biomarkers, played an active role in business development to grow the Biogen Idec discovery pipeline and published seminal research findings characterizing the mechanisms of action of Tecfidera, Biogen Idec. Rhodes spent a combined 1. Johnson & Johnson Pharmaceutical Research and Development, LLC (now Janssen), and at Wyeth, where he pursued innovative approaches to the identification of novel ion channel modulators for the treatment of central nervous system diseases. Dr. Rhodes earned his Ph. D. Prior to Yumanity, Dr. Le Bourdonnec served as vice president discovery chemistry & pharmaceutical research at Cubist Pharmaceuticals, where he led a team of chemists dedicated to the discovery of novel antibacterials and human disease therapeutics. Le Bourdonnec joined the biopharmaceutical industry in 2. Adolor Corporation and held positions of increasing responsibility in the discovery group. Le Bourdonnec joined Cubist. Le Bourdonnec received his chemical engineering degree from the Ecole Nationale Sup. Le Bourdonnec moved to the United States in 1. University of Minnesota (Minneapolis), where he worked, under the supervision of Professor Philip S. Portoghese, distinguished Professor of Medicinal Chemistry, in the design and synthesis of affinity labels for the opioid receptors. Dr. Le Bourdonnec is co- author of 3. U. S. Robert Scannevin joined Yumanity Therapeutics in April of 2. He joins us most recently from Biogen, where he served in various positions of increasing responsibility culminating as a senior director in the Neurology Discovery department. Scannevin led research initiatives at Wyeth (now Pfizer) and Johnson & Johnson Pharmaceutical Research and Development (now Janssen). In his time at Biogen, Dr. Scannevin led discovery programs in Alzheimer. Scannevin made key contributions to several other discovery programs that have transitioned into clinical development and was heavily involved in the development of dimethyl fumarate (Tecfidera), where he led preclinical research activity focused on elucidating the mechanism of action of this first- in- class oral therapy. Scannevin is a recognized leader in the field of fumarate biology. Prior to starting a research career in industry, Dr. Scannevin earned his Ph. D. Trimmer, and received postdoctoral training at the Johns Hopkins University School of Medicine in the laboratory of Dr. He is a co- author on more than 4. Scientific Founder. Susan Lindquist, Ph. D. Scientific Founder. Dr. Lindquist is the scientific founder of Yumanity Therapeutics. She is a pioneer in the field of protein folding and has provided transformative insights on its multifaceted roles in normal biology and human disease. Her seminal work on heat- shock protein 9. Hsp. 90), a chaperone protein that assists other proteins in folding, led to new understandings of evolutionary processes, including the emergence and evolution of cancer and the emergence of microbial drug resistance. She defined mechanisms of prion and amyloid formation and propagation. Most recently, she developed Yumanity. Lindquist is a member and former director of the Whitehead Institute, an investigator in the Howard Hughes Medical Institute, and a professor of biology at MIT. A member of the National Academy of Sciences and the Institute of Medicine, her honors also include the E. B. Wilson Award, the Dickson Prize in Medicine, the Otto- Warburg Prize, the Genetics Society of America Medal, the FASEB Excellence in Science Award, the Max Delbr. In 2. 00. 9, she was awarded the National Medal of Science, our nation. Lindquist is also a member of the board of directors of Johnson & Johnson. She previously co- founded Fold. Rx (acquired by Pfizer), a company that developed tafamidis, a first- in- class drug now approved to combat hereditary peripheral amyloidosis, another important genetically based protein misfolding disease of the nervous system. Scientific Co- Founders. Vikram Khurana, M. D., Ph. D. Senior Advisor, Discovery Technologies. Dr. Vikram (Vik) Khurana is a scientific co- founder of Yumanity who spearheaded the stem- cell platforms that are core to the company’s discovery approach. He currently serves as its Senior Advisor (Discovery Technologies), and from July 2. September 2. 01. 6 was Vice President, Discovery Technologies. Khurana is also a Principal Investigator and attending neurologist within the Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital, Principal Faculty at the Harvard Stem Cell Institute, and an attending neurologist at Brigham and Women’s Hospital. Khurana is a medical graduate of the University of Sydney, Australia, and came to Boston as a Fulbright Scholar in 2. Ph. D. He completed his residency in neurology and Fellowship training in movement disorders and ataxia at Brigham and Women. From 2. 01. 0 to 2. Visiting Scientist at the Whitehead Institute in the laboratories of Susan Lindquist and Rudolf Jaenisch. Chee Yeun Chung, Ph. D. Associate Director, Assay Development. Dr. Chung is a member of Yumanity. Chung is a graduate of Ewha Woman. She then obtained her Ph. D. Prior to joining Yumanity, she was an instructor at Harvard Medical School, subsequently joining the Lindquist lab at the Whitehead Institute as a senior research scientist in 2. She developed assays that have identified abnormalities in rat and human i. PSc- based cortical neuron culture system, revealing critical mechanisms of neurodegenerative diseases. Daniel Tardiff, Ph. D. Associate Director, Yeast Phenotypic Screening. Dr. Tardiff is a member of Yumanity. Prior to joining Yumanity, Dr. Tardiff was a member of the Lindquist lab at the Whitehead Institute since 2. His work there was instrumental in the analysis of the toxicity resulting from alpha- synuclein expression. His genetic and chemical screens of yeast expressing alpha- synuclein have delineated basic cellular processes disrupted by alpha- synuclein as well as compounds that alleviate alpha- synuclein toxicity. Tardiff obtained his B.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
December 2016
Categories |